$MDGL
MADRIGAL PHARMACEUTICALS, INC. Stock $mdgl

$mdgl Overview Financials Valuation SEC Filings Company Website

2014 Q1 Form 10-K Financial Statement

#000104746914002088 Filed on March 11, 2014

Income Statement

Concept	2014 Q1	2013 Q4	2013 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.300M	$3.500M	$4.200M
YoY Change	35.9%	2.94%	50.0%
% of Gross Profit
Research & Development	$17.58M	$19.98M	$17.62M
YoY Change	7.34%	39.23%	50.07%
% of Gross Profit
Depreciation & Amortization	$168.0K	$150.0K	$100.0K
YoY Change	68.0%	25.0%	-50.0%
% of Gross Profit
Operating Expenses	$22.91M	$23.44M	$21.79M
YoY Change	13.08%	32.43%	49.9%
Operating Profit	-$22.91M	-$23.44M	-$21.79M
YoY Change	13.08%	32.43%	49.9%
Interest Expense	-$650.0K	-$718.0K	-$721.0K
YoY Change	38.3%	70.95%	57.77%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$23.60M	-$24.20M	-$22.50M
YoY Change	14.01%	33.7%	50.0%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$23.60M	-$24.20M	-$22.50M
YoY Change	14.01%	33.7%	50.0%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$9.833M	-$11.00M	-$11.25M
COMMON SHARES
Basic Shares Outstanding	85.44M shares	69.11M shares	69.06M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q1	2013 Q4	2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$78.80M	$91.50M	$53.40M
YoY Change	-12.83%	-9.05%	-3.09%
Cash & Equivalents	$52.03M	$48.49M	$25.48M
Short-Term Investments	$26.80M	$43.00M	$27.90M
Other Short-Term Assets	$1.600M	$800.0K	$1.400M
YoY Change	6.67%	0.0%	75.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$80.39M	$92.24M	$54.74M
YoY Change	-12.49%	-9.02%	-2.07%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.408M	$1.553M	$1.488M
YoY Change	4.3%	32.28%	23.49%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$384.0K	$1.409M	$433.0K
YoY Change	-20.17%	207.64%	-7.08%
Total Long-Term Assets	$1.792M	$2.962M	$1.921M
YoY Change	-2.13%	81.5%	12.14%
TOTAL ASSETS
Total Short-Term Assets	$80.39M	$92.24M	$54.74M
Total Long-Term Assets	$1.792M	$2.962M	$1.921M
Total Assets	$82.18M	$95.20M	$56.66M
YoY Change	-12.29%	-7.59%	-1.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.810M	$6.589M	$5.693M
YoY Change	1.59%	16.39%	54.28%
Accrued Expenses	$17.30M	$16.10M	$12.80M
YoY Change	124.68%	62.63%	72.97%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$9.300M	$9.500M	$7.400M
YoY Change	200.0%	20.25%	-6.33%
Total Short-Term Liabilities	$32.37M	$32.21M	$25.93M
YoY Change	95.55%	37.13%	36.73%
LONG-TERM LIABILITIES
Long-Term Debt	$11.60M	$13.90M	$16.10M
YoY Change	-43.41%	208.89%	147.69%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$11.60M	$13.91M	$16.12M
YoY Change	-43.56%	211.42%	149.61%
TOTAL LIABILITIES
Total Short-Term Liabilities	$32.37M	$32.21M	$25.93M
Total Long-Term Liabilities	$11.60M	$13.91M	$16.12M
Total Liabilities	$43.96M	$46.11M	$42.05M
YoY Change	18.5%	64.97%	65.41%
SHAREHOLDERS EQUITY
Retained Earnings	-$575.0M	-$551.4M	-$527.3M
YoY Change		19.56%	18.99%
Common Stock	$613.2M	$600.5M	$541.9M
YoY Change	13.86%	11.97%	14.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$38.22M	$49.09M	$14.61M
YoY Change
Total Liabilities & Shareholders Equity	$82.18M	$95.20M	$56.66M
YoY Change	-12.29%	-7.59%	-1.65%

Cashflow Statement

Concept	2014 Q1	2013 Q4	2013 Q3
OPERATING ACTIVITIES
Net Income	-$23.60M	-$24.20M	-$22.50M
YoY Change	14.01%	33.7%	50.0%
Depreciation, Depletion And Amortization	$168.0K	$150.0K	$100.0K
YoY Change	68.0%	25.0%	-50.0%
Cash From Operating Activities	-$20.27M	-$18.69M	-$16.59M
YoY Change	-8.73%	49.16%	25.11%
INVESTING ACTIVITIES
Capital Expenditures	$23.00K	-$80.00K	-$20.00K
YoY Change	-91.67%	-11.11%	-90.48%
Acquisitions
YoY Change
Other Investing Activities	$16.22M	-$15.06M	$8.510M
YoY Change	-144.63%	-328.18%	-228.36%
Cash From Investing Activities	$16.20M	-$15.15M	$8.500M
YoY Change	-144.24%	-332.36%	-224.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$10.12M
YoY Change	868.23%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	7.620M	56.85M	-210.0K
YoY Change	-37.95%	-2.12%	-100.88%
NET CHANGE
Cash From Operating Activities	-20.27M	-18.69M	-16.59M
Cash From Investing Activities	16.20M	-15.15M	8.500M
Cash From Financing Activities	7.620M	56.85M	-210.0K
Net Change In Cash	3.550M	23.01M	-8.300M
YoY Change	-107.63%	-55.81%	-315.58%
FREE CASH FLOW
Cash From Operating Activities	-$20.27M	-$18.69M	-$16.59M
Capital Expenditures	$23.00K	-$80.00K	-$20.00K
Free Cash Flow	-$20.29M	-$18.61M	-$16.57M
YoY Change	-9.75%	49.6%	26.97%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2011Q1	snta	Amount Of Grant Awarded AmountOfGrantAwarded	1000000	USD
CY2013	us-gaap	Revenue From Grants RevenueFromGrants	0	USD
CY2012	us-gaap	Revenue From Grants RevenueFromGrants	147000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-551412000	USD
CY2013Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	91500000	USD
CY2013	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="FONT-FAMILY: times;"><font size="2"><b>Use of Estimates</b></font></p> <p style="FONT-FAMILY: times;"><font size="2">        The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant items subject to such estimates and assumptions include contract research accruals, recoverability of long-lived assets, measurement of stock-based compensation, and the periods of performance under collaborative research and development agreements. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</font></p> </div>
CY2011	us-gaap	Revenue From Grants RevenueFromGrants	853000	USD
CY2013	snta	Collaborative Revenues CollaborativeRevenues	0	USD
CY2011	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-6731000	USD
CY2011	snta	Collaborative Revenues CollaborativeRevenues	6731000	USD
CY2013	snta	Patent Expenses PatentExpenses	2900000	USD
CY2012	snta	Patent Expenses PatentExpenses	1800000	USD
CY2011	snta	Patent Expenses PatentExpenses	2300000	USD
CY2012	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	533000	USD
CY2012Q4	snta	Cash And Cash Equivalents And Available For Sale Securities Gross Unrealized Gains CashAndCashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGains	3000	USD
CY2012Q4	snta	Cash And Cash Equivalents And Available For Sale Securities Gross Unrealized Losses CashAndCashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLosses	1000	USD
CY2013Q4	snta	Cash And Cash Equivalents And Available For Sale Securities Gross Unrealized Gains CashAndCashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGains	18000	USD
CY2013Q4	snta	Cash And Cash Equivalents And Available For Sale Securities Gross Unrealized Losses CashAndCashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLosses	1000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	22029000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	21270000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	20476000	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	20096000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1553000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1174000	USD
CY2013	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	516000	USD
CY2012	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	738000	USD
CY2011	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1464000	USD
CY2013	snta	Common Stock Voting Rights Number CommonStockVotingRightsNumber	1	vote
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3322000	USD
CY2011	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3354000	USD
CY2013Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	13026000	USD
CY2013	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y8M12D
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3137000	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3272000	USD
CY2013Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1585000	USD
CY2012Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	999000	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	996000	USD
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	856000	USD
CY2013Q4	snta	Accrued Liabilities Current Excluding Accrued Contract Research Costs AccruedLiabilitiesCurrentExcludingAccruedContractResearchCosts	5718000	USD
CY2012Q4	snta	Accrued Liabilities Current Excluding Accrued Contract Research Costs AccruedLiabilitiesCurrentExcludingAccruedContractResearchCosts	5127000	USD
CY2013	dei	Entity Registrant Name EntityRegistrantName	SYNTA PHARMACEUTICALS CORP
CY2013	dei	Entity Central Index Key EntityCentralIndexKey	0001157601
CY2013	dei	Document Type DocumentType	10-K
CY2013	dei	Document Period End Date DocumentPeriodEndDate	2013-12-31
CY2013	dei	Amendment Flag AmendmentFlag	false
CY2013	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2013	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2013	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2013	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2013	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2013	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2013Q2	dei	Entity Public Float EntityPublicFloat	195204458.70	USD
CY2014Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	85435631	shares
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	48490000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	81512000	USD
CY2012Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	19087000	USD
CY2012Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	13000	USD
CY2013Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	9451000	USD
CY2012Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	7924000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	32207000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	23486000	USD
CY2013Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	85000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	765000	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	786000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	92241000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	101385000	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1409000	USD
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	458000	USD
CY2013Q4	us-gaap	Assets Assets	95203000	USD
CY2012Q4	us-gaap	Assets Assets	103017000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6589000	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5661000	USD
CY2013Q4	snta	Accrued Contract Research Costs AccruedContractResearchCosts	10407000	USD
CY2012Q4	snta	Accrued Contract Research Costs AccruedContractResearchCosts	4761000	USD
CY2013Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	42000	USD
CY2013Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	13820000	USD
CY2013Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	13905000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	46112000	USD
CY2012Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	1000	USD
CY2012Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	4464000	USD
CY2012Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4465000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	27951000	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	9000	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	7000	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	600477000	USD
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	536277000	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	17000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-461220000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	49091000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	75066000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	95203000	USD
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	85232506	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	68930082	shares
CY2011	snta	License And Milestone Revenues LicenseAndMilestoneRevenues	6731000	USD
CY2012	snta	Total Revenues TotalRevenues	147000	USD
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15699000	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	87559000	USD
CY2013	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-90192000	USD
CY2013	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-2633000	USD
CY2012	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	49412000	USD
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11676000	USD
CY2013	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	15000	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-87559000	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-90177000	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-60941000	USD
CY2012	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1849000	USD
CY2012	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-62790000	USD
CY2011	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	41464000	USD
CY2011	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11552000	USD
CY2011	us-gaap	Operating Expenses OperatingExpenses	53016000	USD
CY2011	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-47380000	USD
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.27
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	70976705	shares
CY2012	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	59411476	shares
CY2011	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.00
CY2011	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	47197572	shares
CY2012	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-1000	USD
CY2012	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-62791000	USD
CY2011	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	6000	USD
CY2011	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-47374000	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	6030000	USD
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	3322000	USD
CY2011	us-gaap	Share Based Compensation ShareBasedCompensation	3354000	USD
CY2011	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-116000	USD
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-21000	USD
CY2013	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	951000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	928000	USD
CY2013	snta	Increase Decrease Accrued Contract And Research Costs IncreaseDecreaseAccruedContractAndResearchCosts	5646000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-77411000	USD
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	225000	USD
CY2012	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-173000	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	2194000	USD
CY2012	snta	Increase Decrease Accrued Contract And Research Costs IncreaseDecreaseAccruedContractAndResearchCosts	1920000	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-54135000	USD
CY2011	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	130000	USD
CY2011	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	265000	USD
CY2013	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	591000	USD
CY2011	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-47300000	USD
CY2013	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	114151000	USD
CY2013	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	90267000	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	769000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-24653000	USD
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	505000	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-9943000	USD
CY2012	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	51437000	USD
CY2011	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-1235000	USD
CY2011	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	27581000	USD
CY2011	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	50726000	USD
CY2011	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	60745000	USD
CY2011	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	690000	USD
CY2011	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	9329000	USD
CY2013	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	13000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	69042000	USD
CY2013	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-33022000	USD
CY2013	us-gaap	Interest Paid InterestPaid	2512000	USD
CY2012	us-gaap	Interest Paid InterestPaid	1696000	USD
CY2011	us-gaap	Interest Paid InterestPaid	1911000	USD
CY2012	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	66248000	USD
CY2012	snta	Proceeds From Issuance Of Common Stock To Related Parties ProceedsFromIssuanceOfCommonStockToRelatedParties	53545000	USD
CY2012	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	32000	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	115515000	USD
CY2011	snta	Proceeds From Issuance Of Common Stock To Related Parties ProceedsFromIssuanceOfCommonStockToRelatedParties	7734000	USD
CY2011	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	2000000	USD
CY2011	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	378000	USD
CY2011	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	201000	USD
CY2011	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	36736000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30075000	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31310000	USD
CY2010Q4	us-gaap	Stockholders Equity StockholdersEquity	23479000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	14774000	USD
CY2013	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="FONT-FAMILY: times;"><font size="2"><b>(1) Nature of Business</b></font></p> <p style="FONT-FAMILY: times;"><font size="2">        Synta Pharmaceuticals Corp. (the Company) was incorporated in March 2000 and commenced operations in July 2001. The Company is a biopharmaceutical company focusing on discovering, developing and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases.</font></p> <p style="FONT-FAMILY: times;"><font size="2">        The Company is subject to risks common to emerging companies in the drug development and pharmaceutical industry including, but not limited to, uncertainty of product development and commercialization, lack of marketing and sales history, dependence on key personnel, uncertainty of market acceptance of products, product liability, uncertain protection of proprietary technology, potential inability to raise additional financing and compliance with the U.S. Food and Drug Administration and other government regulations.</font></p> <p style="FONT-FAMILY: times;"><font size="2">        The Company has incurred significant operating losses since its inception and, as a result, at December 31, 2013 had an accumulated deficit of $551.4 million. Operations have been funded principally through the sale of common stock and convertible preferred stock, capital leases, non-refundable payments under the former collaboration agreements with GlaxoSmithKline (GSK) and Hoffman-La Roche (Roche), and proceeds from term loans by General Electric Capital Corporation (GECC) and Oxford Finance Corporation (Oxford) (see Note 9). At December 31, 2013, the Company had approximately $91.5 million in cash, cash equivalents and marketable securities.</font></p> <p style="FONT-FAMILY: times;"><font size="2">        Based on the Company's current operating levels, it expects its cash resources will be sufficient to fund operations at least through the end of 2014. This estimate assumes that certain activities contemplated for 2014 will be conducted subject to the availability of sufficient financial resources. The Company expects to continue evaluating additional potential sources of funding, including partnership agreements, cost or risk-sharing agreements, equity financings or other sources.</font></p> <p style="FONT-FAMILY: times;"><font size="2">        The Company may require significant additional funds earlier than it currently expects in order to conduct additional clinical trials and continue to fund its operations. There can be no assurances, however, that additional funding will be available on favorable terms, or at all. If adequate funds are not available, the Company may be required to delay, significantly modify or terminate its research and development programs or reduce its planned commercialization efforts.</font></p> </div>
CY2011	snta	Stock Issued During Period Value New Issues Excluding Sales To Related Parties StockIssuedDuringPeriodValueNewIssuesExcludingSalesToRelatedParties	27102000	USD
CY2011	snta	Stock Issued During Period Value Related Party StockIssuedDuringPeriodValueRelatedParty	7734000	USD
CY2011	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	479000	USD
CY2011	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	3354000	USD
CY2012	snta	Stock Issued During Period Value New Issues Excluding Sales To Related Parties StockIssuedDuringPeriodValueNewIssuesExcludingSalesToRelatedParties	65107000	USD
CY2012	snta	Stock Issued During Period Value Related Party StockIssuedDuringPeriodValueRelatedParty	53545000	USD
CY2012	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1141000	USD
CY2012	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	32000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	200067000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	170189000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	170557000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	143988000	USD
CY2012	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	21400000	USD
CY2011	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	16400000	USD
CY2013	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	29900000	USD
CY2013	snta	Deductions Related To Exercise Of Common Stock Options Included In Net Operating Loss Carryforwards DeductionsRelatedToExerciseOfCommonStockOptionsIncludedInNetOperatingLossCarryforwards	1300000	USD
CY2013	snta	Number Of Non Cancelable And Renewable Operating Leases NumberOfNonCancelableAndRenewableOperatingLeases	3	lease
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	2190000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	2226000	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	3322000	USD
CY2013	snta	Stock Issued During Period Value New Issues Excluding Sales To Related Parties StockIssuedDuringPeriodValueNewIssuesExcludingSalesToRelatedParties	37629000	USD
CY2013	snta	Stock Issued During Period Value Related Party StockIssuedDuringPeriodValueRelatedParty	19437000	USD
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1106000	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	6030000	USD
CY2013Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	17623000	USD
CY2013	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	2200000	USD
CY2012	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	2200000	USD
CY2011	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1900000	USD
CY2013Q4	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	45000	USD
CY2013Q4	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	45000	USD
CY2013Q4	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	134000	USD
CY2013Q4	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	7000	USD
CY2013Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	127000	USD
CY2013	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06	pure
CY2013	snta	Income Tax Reconciliation State And Local Operating Loss Expiration Amount IncomeTaxReconciliationStateAndLocalOperatingLossExpirationAmount	661000	USD
CY2013	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1118000	USD
CY2013	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	2462000	USD
CY2013	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-47000	USD
CY2013	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	29878000	USD
CY2012	snta	Income Tax Reconciliation State And Local Operating Loss Expiration Amount IncomeTaxReconciliationStateAndLocalOperatingLossExpirationAmount	3167000	USD
CY2012	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	382000	USD
CY2012	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	411000	USD
CY2012	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	22000	USD
CY2012	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	21409000	USD
CY2011	snta	Income Tax Reconciliation State And Local Operating Loss Expiration Amount IncomeTaxReconciliationStateAndLocalOperatingLossExpirationAmount	2867000	USD
CY2011	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	373000	USD
CY2011	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	1537000	USD
CY2011	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	259000	USD
CY2011	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	16442000	USD
CY2013	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-3735000	USD
CY2012	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-3220000	USD
CY2011	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2379000	USD
CY2011	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	84000	USD
CY2013	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-30665000	USD
CY2012	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-21349000	USD
CY2011	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-16109000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	19675000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	2412000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	6254000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1169000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	17225000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	2594000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	5368000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1014000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	200067000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	170189000	USD
CY2013	snta	Defined Contribution Plan Employers Matching Contribution Vesting Period DefinedContributionPlanEmployersMatchingContributionVestingPeriod	P3Y
CY2013	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	413000	USD
CY2012	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	376000	USD
CY2011	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	372000	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2012Q1	us-gaap	Revenue From Grants RevenueFromGrants	147000	USD
CY2012Q1	snta	Total Revenues TotalRevenues	147000	USD
CY2012Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2646000	USD
CY2012Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2882000	USD
CY2012Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2796000	USD
CY2012Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3352000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1995000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	25000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	6436000	USD
CY2013Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3878000	USD
CY2013Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4187000	USD
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4171000	USD
CY2013Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3463000	USD
CY2012Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	12066000	USD
CY2012Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	11252000	USD
CY2012Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	11743000	USD
CY2012Q4	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	14351000	USD
CY2013Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	16380000	USD
CY2013Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	17876000	USD
CY2013Q4	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	19981000	USD
CY2012Q1	us-gaap	Operating Expenses OperatingExpenses	14712000	USD
CY2012Q2	us-gaap	Operating Expenses OperatingExpenses	14134000	USD
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	22063000	USD
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	21794000	USD
CY2013Q4	us-gaap	Operating Expenses OperatingExpenses	23444000	USD
CY2012Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-14565000	USD
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-14134000	USD
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-14539000	USD
CY2012Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-17703000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-20258000	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-22063000	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-21794000	USD
CY2013Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-23444000	USD
CY2012Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-486000	USD
CY2012Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-486000	USD
CY2012Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-457000	USD
CY2012Q4	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-420000	USD
CY2013Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-470000	USD
CY2013Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-724000	USD
CY2013Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-721000	USD
CY2013Q4	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-718000	USD
CY2012Q3	us-gaap	Operating Expenses OperatingExpenses	14539000	USD
CY2012Q4	us-gaap	Operating Expenses OperatingExpenses	17703000	USD
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	20258000	USD
CY2012Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15051000	USD
CY2012Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14620000	USD
CY2012Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14996000	USD
CY2012Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18123000	USD
CY2013Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20728000	USD
CY2013Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22787000	USD
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22515000	USD
CY2013Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24162000	USD
CY2012Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.25
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.25
CY2012Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.29
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.30
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.33
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.33
CY2013Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.31
CY2012Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	56366992	shares
CY2012Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	57650412	shares
CY2012Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	60661720	shares
CY2012Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	62914546	shares
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	68991371	shares
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	69034823	shares
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	69047161	shares
CY2013Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	76769199	shares
CY2013Q4	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	44000	USD
CY2013Q4	snta	Reserves For Uncertain Tax Positions ReservesForUncertainTaxPositions	0	USD
CY2012Q4	snta	Reserves For Uncertain Tax Positions ReservesForUncertainTaxPositions	0	USD
CY2011Q4	snta	Reserves For Uncertain Tax Positions ReservesForUncertainTaxPositions	0	USD
CY2013	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2011	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	400000	USD
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2012	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2012	snta	Collaborative Revenues CollaborativeRevenues	0	USD
CY2012Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2013Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	9214000	USD
CY2013Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	4606000	USD
CY2013Q4	us-gaap	Secured Debt SecuredDebt	23271000	USD
CY2013	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	126000	USD
CY2013Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	9451000	USD
CY2013	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	5252000	USD

Files In Submission

Name	View Source	Status
0001047469-14-002088-index-headers.html	Edgar Link	pending
0001047469-14-002088-index.html	Edgar Link	pending
0001047469-14-002088.txt	Edgar Link	pending
0001047469-14-002088-xbrl.zip	Edgar Link	pending
a2218862z10-k.htm	Edgar Link	pending
a2218862zex-10_36.htm	Edgar Link	pending
a2218862zex-21_1.htm	Edgar Link	pending
a2218862zex-23_1.htm	Edgar Link	pending
a2218862zex-31_1.htm	Edgar Link	pending
a2218862zex-31_2.htm	Edgar Link	pending
a2218862zex-32_1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
g1045185.jpg	Edgar Link	pending
g134154.jpg	Edgar Link	pending
g271545.jpg	Edgar Link	pending
g352864.jpg	Edgar Link	pending
g434304.jpg	Edgar Link	pending
g980502.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
snta-20131231.xml	Edgar Link	completed
snta-20131231.xsd	Edgar Link	pending
snta-20131231_cal.xml	Edgar Link	unprocessable
snta-20131231_def.xml	Edgar Link	unprocessable
snta-20131231_lab.xml	Edgar Link	unprocessable
snta-20131231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MDGL
MADRIGAL PHARMACEUTICALS, INC. Stock $mdgl

2014 Q1 Form 10-K Financial Statement

#000104746914002088 Filed on March 11, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDGL MADRIGAL PHARMACEUTICALS, INC. Stock $mdgl

2014 Q1 Form 10-K Financial Statement

#000104746914002088 Filed on March 11, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDGL
MADRIGAL PHARMACEUTICALS, INC. Stock $mdgl